Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3Recruiting 2Not yet recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1

Conditions

Lung Neoplasms 21Multiple Myeloma 20Neoplasm Metastasis 18Lymphoma 16Leukemia, Myeloid, Acute 15Breast Neoplasms 14Prostatic Neoplasms 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Ovarian Neoplasms 11Melanoma 10Glioma 10Fallopian Tube Neoplasms 10Urinary Bladder Neoplasms 9Pancreatic Neoplasms 9Triple Negative Breast Neoplasms 8Sarcoma 8Carcinoma, Renal Cell 8Medulloblastoma 7Cholangiocarcinoma 7Burkitt Lymphoma 7Small Cell Lung Carcinoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Oropharyngeal Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia, Biphenotypic, Acute 6Glioblastoma 6Endometrial Neoplasms 6Carcinosarcoma 6Uterine Cervical Neoplasms 5

Interventions

avelumab 7Nivolumab 5pembrolizumab 4Specimen Handling 3Ipilimumab 3Biopsy 3cemiplimab 2atezolizumab 2Radiotherapy 2Magnetic Resonance Spectroscopy 2tocilizumab 1talimogene laherparepvec 1prednylidene 1poly ICLC 1lutetium Lu 177 dotatate 1lenvatinib 1fludarabine phosphate 1fludarabine 1flt3 ligand protein 1durvalumab 1deltacortene 1Tacrolimus 1Saline Solution 1Radiosurgery 1Radiation 1Prednisone 1MAPRE1 protein, human 1Lutetium-177 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Merkel Cell × Specimen Handling × Clear all
NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

NCT05947500 2026-05-13

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT06056895 2026-01-15

TRICK-MCC

University of Washington

Phase 2 Active not recruiting
12 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡